| 查看: 413 | 回复: 0 | |||
chao1.zhang银虫 (小有名气)
|
[交流]
罗氏抗体-药物偶合新药上市，又一系列重磅开始？
|
|
Trastuzumab emtansine (INN; in the United States, ado-trastuzumab emtansine, trade name Kadcyla) is an antibody-drug conjugate consisting of the monoclonal antibody trastuzumab (Herceptin) linked to the cytotoxic agent mertansine (DM1).Trastuzumab alone kills cancer cells by binding to the HER2 receptor. The conjugate includes emtansine, which enters the cell and destroys the cell by binding to tubulin.Because monoclonal antibodies target HER2, and HER2 is only expressed in breast cancer cells, the conjugate delivers the toxin emtansine only to breast cancer cells.Meet the Bay Area's next blockbuster drug: T-DM1, a breast cancer-fighting treatment developed by Genentech Inc., leads the early Class of 2013 drugs seeking Food and Drug Administration approval. The FDA's decision date is Feb. 26. In the EMILIA clinical trial of women with advanced HER2 positive breast cancer who were already resistant to trastuzumab alone, it improved survival by 5.8 months compared to the combination of lapatinib and capecitabine. Based on that trial, the U.S. FDA approved marketing on February 22, 2013. |
回复此楼» 猜你喜欢
SUES&NERCN课题组接受硕士生调剂 (学硕1名+专硕1名)
已经有0人回复
-
SUES&NERCN课题组接受硕士生调剂 (学硕1名+专硕1名)
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有252人回复
-
非全日制公共管理求调剂
已经有0人回复
-
药学298分-一志愿中国海洋大学-求调剂
已经有1人回复
-
【#上海调剂急录#】能接受985联合培养的速来！带你发一区文章！
已经有3人回复
-
【上海调剂】985联合培养！别错过能送你去丹麦/交大/同济/中科院的神仙导师！
已经有0人回复
-
【调剂上岸】985联合培养！1007/1055/08/07等，不限专业，想联培的速来！
已经有2人回复
-
【上海调剂】985联合培养！别错过能送你去丹麦/交大/同济/中科院的神仙导师！
已经有7人回复
-
【#上海调剂急录#】能接受985联合培养的速来！带你发一区文章！
已经有4人回复
